AbbVie Inc. (ABBV) Valuation — DCF & Advanced Analysis | MarketCI

Navigation

Explore Analysis Investor Relations AI Assistant Compare Screener

Help Pricing Privacy Terms

Navigation

Explore Analysis Investor Relations AI Assistant Compare Screener

Help Pricing Privacy Terms

AbbVie Inc. (ABBV) Valuation — DCF & Advanced Analysis | MarketCI | MarketCI

ABBV

Market Closed

AbbVie Inc.

NYSEHealthcare Drug Manufacturers - General

55.00K employees

CEO: Robert A. Michael

Founded: 2013

$251.52

+$0.00(+NaN%)

Market Cap

444.38B

Beta

0.31

52W Range

N/A

Dividend Yield

2.68%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

Comprehensive Valuation

In-depth valuation analysis including DCF scenarios and peer comparisons.

AI Insight: AbbVie's current price exceeds the PERT-weighted fair value by 25%, indicating potential overvaluation with high downside risk (83.3% scenarios below current price). Financial health reveals low profitability and growth amid high leverage, increasing volatility (40.19% coefficient of variation). Analyst targets and trading range suggest some optimism, but overall valuation signals elevated investment risk.

Enhanced Football Field Analysis

Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore ABBV

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples